Hematologic Malignancies Market Report

Hematologic Malignancies Market Analysis by Type (Leukemia, Lymphoma, Multiple Myeloma), By Therapy (Chemotherapy, Radiotherapy, Immunotherapy), And Segment Forecasts, 2014 - 2025

Published: September 2017  |  113 Pages  |  Format: PDF  |  Report ID: GVR-1-68038-687-5

Industry Insights

The global hematologic malignancies market size was valued at USD 35.6 billion in the year 2016 with a CAGR of 10.48%. Growing incidence of blood cancer and increasing focus on development of new treatments are expected to drive the growth. Globally, blood malignancies are the fifth most common cancer and is the second most leading cause of cancer deaths. The three most common types of blood cancers are leukemia, lymphoma, and multiple myeloma. Worldwide, more than 300,000 people are diagnosed with leukemia and 400,000 people are diagnosed with lymphoma each year 

The highest number of acquisitions and collaborations are happening in the oncology segment where big pharma players are collaborating with each other. In 2015, cancer therapeutics witnessed the significant number of collaborations, which reflects the interest in this segment. Various organizations and research institutes around the world are collaborating to develop novel therapies for hematologic malignancies.

U.S. hematologic malignancies market by type, 2014 - 2025 (USD Billion)

U.S. hematologic malignancies market

Furthermore, formulations of new regulatory approvals for new drugs for blood cancer is expected to boost the growth of this market. For instance, in 2015, Pfizer announced that inotuzumab (antibody-drug conjugate) received a breakthrough therapy designation from U.S. FDA for acute lymphoblastic leukemia.

Increasing awareness amongst healthcare professionals and patients about possibility of early diagnosis of cancer and increase in government funding for research are anticipated to accelerate the market growth during the forecast period. Institutes like National Cancer Institute (NCI) receive funds from U.S. congress to support cancer-related activities. 

Type Insights

Based on type, the market is categorized into leukemia, lymphoma, and multiple myeloma. Leukemia is further categorized into acute lymphocytic, chronic lymphocytic, acute myeloid, and chronic myeloid leukemia. Acute lymphocytic leukemia is most prevalent type of leukemia, which accounted for 56% of cases in adolescents and 80% in children during 2016 to 2017. 

Leukemia was the largest segment in 2016, owing to the presence of best-selling brands like Rituxan, Imbruvica, and Glivec, which are reported to be some of the highest revenue generating oncology drugs. Acute myeloid is expected to witness the fastest growth over the forecast period due to the presence of a strong product pipeline and their expected commercialization.

Therapy Insights

The therapy segment is further categorized into chemotherapy, radiotherapy, immunotherapy, and stem cell transplantation. Chemotherapy was the largest segment in 2016, as it is the first line of treatment. For most types of blood cancer, chemotherapy is the usual treatment and a particular drug or combination of drugs are used, based on the type of cancer. 

Immunotherapy is estimated to witness fastest growth of 11.2% over the forecast. Effectiveness of the treatment, lower adverse effects, and presence of brands like Rituxan, Revlimid, Mabthera, Gazyva, and Arzerra are responsible for the growth of this segment.

Global hematologic malignancies market by region, 2016 (%)

Global hematologic malignancies market

Regional Insights

North America dominated the hematologic malignancy market, and it held the market share of over 39% in 2016. Presence of key players, established healthcare infrastructure, and availability of branded drugs are some of the factors responsible for its large share. Besides, favorable government initiatives and increase in number of research collaborations are some of the drivers expected to accelerate the market growth. 

Asia Pacific is estimated to be the fastest growing over the forecast period with CAGR of around 12.5%, owing to the increase in healthcare expenditure, rising awareness about early diagnosis, high unmet clinical needs of patients, and availability of effective treatment in emerging countries, such as China and India.

Competitive Insights

Some of the key players in this industry are Pfizer, Inc.; F. Hoffmann-LA Roche ltd; Sanofi-Aventis; Bristol-Myers Squibb Company; AbbVie, Inc.; Novartis AG; GlaxoSmithKline PLC; Celgene Corporation; Johnson & Johnson Services, Inc.; and Takeda Pharmaceutical Company limited.

Key players are focusing on expanding their businesses in developing regions to increase their market share. In addition, they are adopting strategies such as mergers & acquisitions and new product development. For instance, AbbVie acquired Pharmacyclics, Inc., a leader in hematologic oncology market. With this acquisition, they aim to expand their presence in scientific and commercial oncology.

Report Scope 

Attribute

Details

Base year for estimation

2016

Actual estimates/Historical data

2014 - 2016

Forecast period

2017 - 2025

Market representation                                    

Revenue in USD Billion and CAGR from 2017 to 2025

Regional scope

North America, Europe, Asia Pacific, Latin America, Middle East & Africa

Country scope

U.S., Canada, Germany, UK, China, Japan, Brazil, South Africa

Report coverage

Revenue forecast, company share, competitive landscape, growth factors and trends

15% free customization scope (equivalent to 5 analyst working days)

If you need specific market information, which is not currently within the scope of the report, we will provide it to you as a part of customization


Segments covered in the report

This report forecasts revenue growth at global, regional & country levels and provides an analysis on the industry trends in each of the sub-segments from 2014 to 2025. For this study, Grand View Research has segmented the global hematologic malignancies market based on type, therapy, and region:

  • Type Outlook (Revenue, USD Billion, 2014 - 2025)

    • Leukemia

      • Acute Lymphocytic Leukemia

      • Chronic Lymphocytic Leukemia

      • Acute Myeloid Leukemia

      • Chronic Myeloid Leukemia

    • Lymphoma

    • Multiple Myeloma

    • Others

  • Therapy Outlook (Revenue, USD Billion, 2014 - 2025)

    • Chemotherapy

    • Radiotherapy

    • Immunotherapy

    • Stem Cell Transplantation

    • Others

  • Regional Outlook (Revenue, USD Billion, 2014 - 2025)

    • North America

      • U.S.

      • Canada

    • Europe

      • Germany

      • UK

    • Asia Pacific

      • China

      • Japan

    • Latin America

      • Brazil

    • Middle East & Africa

      • South Africa

Key questions answered by the report
Request for Customization

Choose License Type:

Single User - $4,950
Multi User - $7,950
Enterprise User - $9,950

Special Pricing & Discounts

Avail customized purchase options to meet your research needs:

  • Buy sections of this report
  • Buy country level reports
  • Request for historical data
  • Request discounts available for Start-Ups & Universities

Why Choose Us

  • Research support

    24/5 Research support

    Get your queries resolved from an industry expert. Request for a free product review before report purchase.

  • Custom research service

    Custom research service

    Speak to the report author to design an exclusive study to serve your research needs.

  • Quality assurance

    Quality assurance

    A testimonial for service excellence represented in the form of BBB "A" Accreditation.

  • BBB Rating dandb
  • Information security

    Information security

    Your personal and confidential information is safe and secure.

  • BOA